Log in
NYSE:ALT

Altimmune Stock Forecast, Price & News

$12.00
+0.32 (+2.74 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$11.30
Now: $12.00
$12.02
50-Day Range
$11.05
MA: $12.87
$14.35
52-Week Range
$1.51
Now: $12.00
$35.10
Volume540,811 shs
Average Volume2.63 million shs
Market Capitalization$394.94 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that is in Phase II clinical trials; HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials; and NasoShield, a vaccine for the prevention of anthrax disease following inhalation of bacterial spores that is in Phase I clinical trials. Its preclinical stage products include SparVax-L, a recombinant protein-based anthrax vaccine; and Oncosyn, an immunotherapeutic for treating cancer. The company also develops veterinary product candidates. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
PhoneN/A
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$394.94 million
Next Earnings Date11/11/2020 (Estimated)
OptionableOptionable
$12.00
+0.32 (+2.74 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALT News and Ratings via Email

Sign-up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Altimmune (NYSE:ALT) Frequently Asked Questions

How has Altimmune's stock been impacted by Coronavirus (COVID-19)?

Altimmune's stock was trading at $3.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ALT shares have increased by 276.2% and is now trading at $12.00.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Altimmune?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Altimmune
.

When is Altimmune's next earnings date?

Altimmune is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Altimmune
.

How were Altimmune's earnings last quarter?

Altimmune, Inc. (NYSE:ALT) issued its quarterly earnings data on Tuesday, August, 11th. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.65. The business earned $0.72 million during the quarter, compared to analysts' expectations of $1 million.
View Altimmune's earnings history
.

Who are some of Altimmune's key competitors?

What other stocks do shareholders of Altimmune own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Altimmune investors own include Vaxart (VXRT), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Novavax (NVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Micron Technology (MU), Crispr Therapeutics (CRSP), Dynavax Technologies (DVAX) and NVIDIA (NVDA).

Who are Altimmune's key executives?

Altimmune's management team includes the following people:
  • Mr. William J. Enright, Pres, CEO & Director (Age 55)
  • Dr. M. Scot Roberts Ph.D., Chief Scientific Officer (Age 59)
  • Dr. Sybil Tasker, Chief Medical Officer (Age 55)
  • Mr. Will Brown, Acting CFO & Principal Accounting Officer (Age 36)
  • Mr. Bertrand Georges Ph.D., Chief Technology Officer

What is Altimmune's stock symbol?

Altimmune trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALT."

How do I buy shares of Altimmune?

Shares of ALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Altimmune's stock price today?

One share of ALT stock can currently be purchased for approximately $12.00.

How big of a company is Altimmune?

Altimmune has a market capitalization of $394.94 million.

What is Altimmune's official website?

The official website for Altimmune is www.altimmune.com.

This page was last updated on 10/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.